Organic Acids
Medchemexpress LLC Cef20 (Tfa) | 99.3% | 1057.19 | 25 MG
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).
- High purity of 99.31%
- Molecular weight of 1057.19
- Solid appearance
- White to off-white color
- Sequence: Asn-Leu-Val-Pro-Met-Val-Ala-Thr-Val (NLVPMVATV)
- Soluble in DMSO
- Store in sealed container, away from moisture
- Powder storage: -80°C for 2 years, -20°C for 1 year
- Storage in solvent: -80°C for 6 months, -20°C for 1 month
Apexbio Technology LLC SCH772984 TFA 942183-80-4 (free base) 5mg
SCH772984 TFA is a small-molecule inhibitor targeting extracellular signal-regulated kinase 1/2 (ERK1/2) It is designed to inhibit ERK catalytic activity thereby blocking phosphorylation of downstream substrates and regulating the RAS-RAF-MEK-ERK signaling pathway SCH772984 TFA exerts its biological activity primarily through direct interaction with ERK1/2 acting as an ATP-competitive inhibitor Based on these pharmacological properties SCH772984 TFA holds research potential in studies examining ERK signaling s role in oncogenic pathway activation tumor cell growth survival mechanisms and resistance phenomena in various cancer models
Medchemexpress LLC Wrwyar-NH2 TFA | 936.07 | 1 MG
Wrwyar-NH2 (TFA) is a control peptide.
- Control peptide for wrwycr-NH2
- Targets DNA/RNA synthesis
- Involved in the cell cycle/DNA damage pathway
Medchemexpress LLC CPP12 (TFA) | 98.7% | 1700.55 | 5 MG
CPP12 TFA is a small, amphiphilic, cyclic cell-penetrating peptide (CPP) in salt form. It binds directly to plasma membrane phospholipids, enters mammalian cells via endocytosis, and is then efficiently released from endosomes. This peptide can be used for intracellular delivery of drugs and chemical probes.
- Small, amphiphilic, cyclic cell-penetrating peptide
- Binds directly to plasma membrane phospholipids
- Enters mammalian cells via endocytosis
- Efficiently released from endosomes
- Used for intracellular delivery of drugs and chemical probes
Medchemexpress LLC SJ1008030 TFA | 2863634-97-1 | 99.81% | 987.96 | 25 MG
SJ1008030 TFA is a JAK2 PROTAC designed to selectively degrade JAK2. This compound has demonstrated potent inhibitory effects on MHH-CALL-4 cell growth with an IC50 of 5.4 nM, making it a valuable tool for leukemia research.
- Selectively degrades JAK2.
- Inhibits MHH-CALL-4 cell growth with an IC50 of 5.4 nM.
- Useful for leukemia research.
- Degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner in MHH-CALL-4 cells.
- Dose-dependently degrades JAK2 and GSPT1 protein in xenograft bone marrow SJBALL021415 cells, indicating the inhibition of the JAK-STAT signaling pathway.
Medchemexpress LLC DOTA-LM3 TFA | 99.3% | 1664.18 | 5 MG
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. The LM3 component refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, which is also a somatostatin antagonist. This product is often isotopically labeled for in vivo tumor tracing, such as 177Lu-DOTA-LM3 TFA and 68Ga-DOTA-LM3 TFA. It can be used for the synthesis and research of Radionuclide-Drug Conjugates (RDCs).
- Acts as an antagonist for somatostatin receptors
- Commonly labeled with isotopes like 177Lu or 68Ga for in vivo tumor tracing
- 68Ga-DOTA-LM3 TFA exhibits favorable biodistribution
- Shows high tumor uptake and good tumor retention
- 68Ga-DOTA-LM3 TFA has few safety concerns
- Useful for research in DOTATOC-negative liver metastases, including pancreatic NET and extensive tumor thrombosis
- Can be utilized for the synthesis and research of Radionuclide-Drug Conjugates (RDCs)
![Medchemexpress LLC Hex-[Cys(tMeBn(H-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH | 99.3% | 1198.40 | 1 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000398288.png-250.jpg)
Medchemexpress LLC Hex-[Cys(tMeBn(H-AET))-Pro-Pro-Thr-Gln-Phe-Cys]-OH | 99.3% | 1198.40 | 1 MG
3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. It is often coupled with radionuclides for tumor diagnosis and research.
- Highly potent FAP-targeting peptide
- Used for theranostics
- Can be coupled with radionuclides
- Suitable for tumor diagnosis and research
Medchemexpress LLC Ncgc00138783 TFA | 00-00-0 | 99.4% | 617.62 g·mol⁻¹ | C28H27F4N7O3S | 5 MG
NCGC00138783 TFA is a small-molecule inhibitor that selectively targets the CD47/SIRPα immune checkpoint, blocking the CD47-SIRPα interaction with reported in vitro activity (IC50 ≈ 50 μM). Supplied as the trifluoroacetic acid (TFA) salt for research applications.
- Selective inhibitor of the CD47/SIRPα immune checkpoint.
- Reported IC50 approximately 50 μM in biochemical assays.
- Supplied as the trifluoroacetic acid (TFA) salt.
- High purity (99.4%).
- Molecular weight 617.62 g·mol⁻¹.
- Store at 4 °C; protect from moisture and light.
Medchemexpress LLC NTPA TFA | 99.8% | 1773.36 (free base) | 5 MG
NTPA TFA is a polycarboxylic acid ligand that participates in the coordination reaction with metal ions to form complexes. It is intended for research use only.
- Purity of 99.80%
- Molecular weight of 1773.36 (free base)
- Formula: C82H161N31O12.xC2HF3O2
- Appearance: Solid
- Color: White to off-white
- Shipping: Room temperature in continental US; may vary elsewhere
- Storage: Sealed storage, away from moisture. Powder: -80°C for 2 years, -20°C for 1 year. In solvent: -80°C for 6 months, -20°C for 1 month (sealed storage, away from moisture)
- Solubility: In vitro: DMSO : 50 mg/mL (need ultrasonic; hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Medchemexpress LLC Dendrotoxin K TFA | 99.5% | 6559.66 (free base) | 1 MG
Dendrotoxin K TFA is a Kv1.1 channel blocker. It determines glutamate release in CA3 neurons in a time-dependent manner through the control of the presynaptic spike waveform.
- Kv1.1 channel blocker
- Determines glutamate release in CA3 neurons
- Controls presynaptic spike waveform
Medchemexpress LLC DPC-AJ1951 TFA | 99.4% | 1666.99 (free base) | 5 MG
This 14 amino acid peptide acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). Its activity has been characterized in ex vivo and in vivo assays of bone resorption.
- Potent agonist of parathyroid hormone (PTH)/PTH-related peptide receptor (PPR)
- Activity characterized in ex vivo and in vivo bone resorption assays
- Induces intracellular Ca2+ mobilization in HEK 293 cells transfected with human PPR
Medchemexpress LLC T-Boc-Met-Asp-Gly-Cys-Glu-Leu | 99.2% | 880.90 | 1 MG
Box5 TFA is a potent Wnt5a antagonist. It inhibits Wnt5a signaling and Wnt5a-mediated Ca2+ release, and also inhibits cell migration. It has the potential for the research of melanoma.
- In vitro: decreases the expression of rWnt5a (0.1 μg/mL) stimulated p-MARCKS in A2058 cells.
Medchemexpress LLC Cys-PKHB1 TFA | 1487.88 | 10MG
Cys-PKHB1 TFA is a peptide conjugated to PKHB1, functioning as a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. It induces mitochondrial alterations, reactive oxygen species generation, and intracellular calcium accumulation, leading to calcium-dependent cell death in breast cancer cells. This compound also activates the immune system in breast cancer cells via immunogenic cell death.
- Conjugated peptide acting as a CD47 agonist
- Thrombospondin-1 peptide mimic
- Exhibits antitumor effects
- Induces mitochondrial alterations
- Promotes reactive oxygen species (ROS) generation
- Causes intracellular calcium (Ca+) accumulation
- Leads to calcium-dependent cell death in breast cancer cells
- Activates the immune system through immunogenic cell death
Medchemexpress LLC Ampreloxetine TFA | 1227056-85-0 | 98.3% | 25 MG
Ampreloxetine TFA (trifluoroacetate) is the TFA salt of ampreloxetine (TD-9855), an orally active inhibitor of norepinephrine and serotonin uptake supplied as a solid research reagent. It is intended for in vitro and preclinical research and is provided in small package sizes with recommended refrigerated storage.
- Potent norepinephrine and serotonin uptake inhibitor.
- Trifluoroacetate (TFA) salt, solid form.
- Purity 98.3%.
- Molecular weight 435.36 g/mol.
- Available in small research sizes, including 25 mg.
- Storage: 4°C sealed; in solvent: -80°C (6 months), -20°C (1 month).
Medchemexpress LLC CRA-2059 TFA | 99.9% | 864.83 | 1 ML
CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ). Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 has the potential for inflammatory bowel disease research.
- Highly specific and selective tryptase inhibitor
- Potential for inflammatory bowel disease research
- Inhibits recombinant human tryptase-β (rHTβ) with a Ki of 620 pM
- Targets tryptase, a trypsin-like serine protease